TESTOSTERONE: A SAFETY UPDATE 2025

[madman]

Professor Michael Zitzmann

We also know hematocrit can be increased by testosterone preparations. It depends on the preparation, and we think that there is data that shows that the threshold of 52-54% should not be surpassed, and men should be controlled for the hematocrit especially in the first year of treatment every 3 months



Hematocrit & Thromboembolic Risk

* TTh increase Hematocrit - clinically relevant at >52-54%

* Recommended: Control Hematocrit every 3 months in the 1st year

TESTOSTERONE: A SAFETY UPDATE (2025)

Prof. Michael Zitzmann

Overall Summary

 

[madman]

Prof. Michael Zitzmann

Androlabs Website

www.androlabs.com

SAC MEETING IN LONDON 2024​

In September 2024, Androlabs held a Scientific Advisory Committee (SAC) meeting in London, bringing together 17 of Europe's most prominent key opinion leaders in men's health and endocrinology to the Royal Society of Medicine. The SAC meeting provided a dynamic forum for open discussion and knowledge sharing, with a focus on testosterone therapy and its effects on men's health.

KEY DISCUSSIONS ON MEN’S HEALTH AND TESTOSTERONE THERAPY​

The meeting included in-depth discussions about key topics such as testosterone's cardiovascular safety, managing haematocrit responses to therapy, and understanding the efficacy of testosterone gels. Attendees agreed on several key points, including improved testosterone management education for healthcare providers. This discussion highlighted the importance of personalised care in testosterone therapy, as well as improving patient compliance during the first few months of treatment.




ANDROLABS SCIENTIFIC ADVISORY COMMITEE (2024)

 

[madman]

Thread 'Cardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond'

May 16, 2025

7 FUTURE RESEARCH DIRECTIONS

While substantial progress has been made in understanding the CV safety of TTh, key areas for future research remain to further refine its application and optimize patient outcomes.


1. Long-term CV outcomes: The TRAVERSE trial and similar studies have reassured us of TTh’s short-to-medium-term CV safety, yet long-term effects, especially across diverse populations, require further investigation. Extended follow-up studies are needed to assess the potential for long-term CV safety in men undergoing decades-long TTh.


2. Personalized medicine...

• madman
• hypogonadism; t-therapy[ cvd; guidelines
• Replies: 4
• Forum: Testosterone and Men's Health Articles

 

[madman]

TESTOSTERONE THERAPY - A SAFETY UPDATE

Learning outcomes for today

 

[madman]

Target organs of testosterone and its metabolites

Hypothalamic-Pituitary-Gonadal Axis

 

[madman]

EAU guideline 2025

Testosterone levels and symptoms

Symptoms and Interactions in Male Hypogonadism

Hormone constellations in Hypogonadism

 

[madman]

Testosterone levels in men related to age (n=10,098)

Testosterone, age and the metabolic syndrome

Optimal Testosterone Levels

 

[madman]

Pathogenesis of Functional Hypogonadism

Effects of Weight Loss on Testosterone Levels

 

[madman]

HEAT-Registry

RESULTS: Total Testosterone

RESULTS: Hematocrit

HEAT Registry: Thresholds for. hematocrit during TrT

HEAT Study: Predictors of hematocrit increase during TTh

https://www.tandfonline.com/doi/10.1080/13685538.2022.2063830?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

 

[madman]

T-Trial: controlled trial in older men with functional hypogonadism

RESULTS:

 

[madman]

Diabetes mellitus

Hypogonadiam increases mortality in men with Type 2 Diabetes Mellitus

 

[madman]

Hematocrit, testosterone and risk of events: the first year is important

 

[madman]

TRAVERSE-Study: Design

TRAVERSE-Study: Patients

TRAVERSE: primary endpoint

TRAVERSE: Anemia

TRAVERSE: Diabetes mellitus

TRAVERSE: Sexuality

 

[madman]

TRAVERSE: Mood

TRAVERSE: prostate safety

 

[madman]

EAU Guideline 2024

 

[madman]

Cardiovascular Safety - newest data

Thread 'Testosterone Therapy and Heart Health: Large Study Finds No Mortality Risk, But Raises Arrhythmia Concerns'

Jul 28, 2025

* our meta-analysis stands as the most up to date analysis restricted to RCTs directed to men aged 40 or older.


* The main fndings were as follows: (1) there were no significant diferences between groups in all-cause mortality, cardiovascular mortality, MI, and stroke; (2) TRT signifcantly increased the incidence of cardiac arrhythmias; (3) TRT was associated with decreased levels of HDL-c; and (4) there was a marginal increase in SBP levels in the TRT group.

Long‑Term Cardiovascular Safety of Testosterone‑Replacement Therapy in Middle‑Aged and Older...

• madman
• hypogonadism; t-therapy; cvd; health
• Replies: 10
• Forum: Testosterone and Men's Health Articles

 

[madman]

TTh in hypogonadal men
Data from mixed registries

 

[madman]

Cognitive. functions and testosterone

 

[madman]

Position Paper - European Expert Panel

TTh is effective in Male Hypogonadism

 

[madman]

Overall Summary